✦ LIBER ✦

Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies

✍ Scribed by Christiansen, Neal P. ;Kennedy, B. J. ;Ochoa, Augusto C. ;Skubitz, Keith M. ;Bach, Fritz H.

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 398 KB
Volume: 17
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950170521

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous infusion of interleukin-2 in

Continuous infusion of interleukin-2 in children with refractory malignancies

✍ Raul C. Ribeiro; Donna Rill; Paula K. Roberson; Wayne L. Furman; Charles B. Prat 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Adoptive immunotherapy for recurrent gli

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2

✍ Randall E. Merchant; Angus J. Grant; Lynn H. Merchant; Harold F. Young 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

Thirteen patients with recurrent glioblastoma were treated with adoptively transferred autologous lymphokine activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Patients' blood mononuclear cells (MNC) obtained by leukapheresis were cultured at 2.5 million MNC per ml for 3 to 5 days i

The requirements for successful immunoth

The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells

✍ Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 907 KB

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the

the influence of autologous lymphokine-a

the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2

✍ Mark R. Albertini; Jeffrey A. Sosman; Jacquelyn A. Hank; Karen H. Moore; Agnes B 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 863 KB

Natural killer cells in children with ma

Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-α and interleukin-2 on natural killer cell function against tumor cell lines

✍ Carlos S. Alvarado; Harry W. Findley; Wing C. Chan; Robert S. Hnath; Aly Abdel-M 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

Natural killer (NK) cells and NK cell activity were determined in three groups (newly diagnosed [n = 211, on therapy [n = 211, and off therapy [n = 181) of children with various types of malignant solid tumors and in a control group (n = 26) by means of Leu-7 and Leu-llb monoclonal antibodies and a

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa